NO990896L - Bidentate metalloproteaseinhibitorer - Google Patents

Bidentate metalloproteaseinhibitorer

Info

Publication number
NO990896L
NO990896L NO990896A NO990896A NO990896L NO 990896 L NO990896 L NO 990896L NO 990896 A NO990896 A NO 990896A NO 990896 A NO990896 A NO 990896A NO 990896 L NO990896 L NO 990896L
Authority
NO
Norway
Prior art keywords
bidentate
compounds
metalloprotease inhibitors
pharmaceutical compositions
inhibitors
Prior art date
Application number
NO990896A
Other languages
English (en)
Other versions
NO990896D0 (no
Inventor
Neil Gregory Almstead
Biswanath De
Rimmi Sandler Bradley
Garry Steven Garrett
Ii John Emory Marlin
John Mcmillan Mciver
Zhe Wang
Yetunde Olabisi Taiwo
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO990896D0 publication Critical patent/NO990896D0/no
Publication of NO990896L publication Critical patent/NO990896L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Cosmetics (AREA)
  • Confectionery (AREA)

Abstract

Oppfinnelsen fremskaffer forbindelser som er nyttige som inhibitorer av metalloproteaser, og som er effektive for å behandle tilstander karakterisert ved overskuddsaktivitet av disse enzymene. Spesielt vedrører den foreliggende oppfinnelse en forbindelse som har en struktur i henhold til formel (I) SCfe-A- Som beskrevet.i kravene, eller en optisk iso- mer, diastereomer eller en antiomer derav, eller et farmasøytisk akseptabelt salt, eller biohydrolyserbare alkoksyamid, ester, acyl- oksyamid eller imid derav. Også brakt for dagen er forbindelser, farmasøytiske sammen- setninger og fremgangsmåter for å behandle sykdommer karakterisert ved metalloprotease- aktivitet ved å bruke disse forbindelsene eller de farmasøytiske sammensetningene inne- holdende disse.
NO990896A 1996-08-28 1999-02-25 Bidentate metalloproteaseinhibitorer NO990896L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2474696P 1996-08-28 1996-08-28
PCT/US1997/014554 WO1998008814A1 (en) 1996-08-28 1997-08-22 Bidentate metalloprotease inhibitors

Publications (2)

Publication Number Publication Date
NO990896D0 NO990896D0 (no) 1999-02-25
NO990896L true NO990896L (no) 1999-04-20

Family

ID=21822181

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990896A NO990896L (no) 1996-08-28 1999-02-25 Bidentate metalloproteaseinhibitorer

Country Status (20)

Country Link
US (1) US6121272A (no)
EP (1) EP0923547A1 (no)
JP (1) JP2000516954A (no)
KR (1) KR20000035921A (no)
CN (1) CN1228767A (no)
AU (1) AU4074097A (no)
BR (1) BR9712792A (no)
CA (1) CA2263914A1 (no)
CO (1) CO5420196A1 (no)
CZ (1) CZ62499A3 (no)
HU (1) HUP0000616A2 (no)
ID (1) ID18417A (no)
IL (1) IL128665A0 (no)
NO (1) NO990896L (no)
PE (1) PE109298A1 (no)
PL (1) PL331803A1 (no)
SK (1) SK24899A3 (no)
TR (1) TR199900401T2 (no)
WO (1) WO1998008814A1 (no)
ZA (1) ZA977697B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006340A2 (en) 1997-07-31 1999-02-11 The Procter & Gamble Company Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
SK11692000A3 (sk) 1998-02-04 2001-02-12 Novartis Ag Sulfonylaminoderiváty, ktoré inhibujú metaloproteinázy degradujúce matricu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
CA2334002A1 (en) 1998-06-03 1999-12-09 Mark H. Norman N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
US6420415B1 (en) 1998-09-21 2002-07-16 Takeda Chemical Industries, Ltd. Thiol compounds, their production and use
PL350452A1 (en) 1999-03-03 2002-12-16 Procter & Gamble Dihetero-substituted metalloprotease inhibitors
HUP0202199A2 (en) 1999-03-03 2002-10-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
WO2001010838A1 (en) * 1999-08-05 2001-02-15 The Procter & Gamble Company Multivalent compounds
WO2001010837A1 (en) * 1999-08-05 2001-02-15 The Procter & Gamble Company Multivalent sulfonamides
CN1536989A (zh) 2000-06-30 2004-10-13 促进全身健康
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
CN1620433A (zh) * 2000-07-19 2005-05-25 霍夫曼-拉罗奇有限公司 作为内皮肽转化酶抑制剂的吡咯烷衍生物
JP3983663B2 (ja) * 2000-07-19 2007-09-26 エフ.ホフマン−ラ ロシュ アーゲー メタロプロテアーゼインヒビターとしてのピロリジン誘導体
CA2415681C (en) 2000-07-19 2008-05-20 F. Hoffmann-La Roche Ag Pyrrolidine derivatives
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2449019A1 (en) * 2001-05-29 2002-12-05 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
WO2004056766A1 (en) * 2002-12-19 2004-07-08 Vertex Pharmaceuticals Incorporated Inhibitors of tace
US7897776B2 (en) 2007-04-23 2011-03-01 Salutria Pharmaceuticals Llc Sulfonamide containing compounds for treatment of inflammatory disorders
CN106905183B (zh) * 2017-02-24 2018-07-31 三峡大学 一类含氨基的ɑ-酰氧基羰基酰胺类衍生物,制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3501489A (en) * 1966-01-21 1970-03-17 American Home Prod 1-phenylsulfonyl-2-(2-thiazolin-2-yl-oxy and thiol) pyrrolidines
US4695575A (en) * 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
IL74140A (en) * 1984-04-10 1988-05-31 Robins Co Inc A H Substituted n-((amino)alkyl)-1-pyrrolidine,-1-piperidine and-1-homopiperidine-carboxamides and pharmaceutical compositions containing them
US4595700A (en) * 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
GB8515934D0 (en) * 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
IT1215590B (it) * 1987-06-29 1990-02-14 Roussel Maestretti Spa Derivati della 1-benzene solfonil 2-oco 5-alchiltio pirrolidina, un loro procedimentodi preparazione e il loro impiegocome stostanze medicinali.
GB8814813D0 (en) * 1988-06-22 1988-07-27 Beecham Group Plc Novel compounds
DE4011172A1 (de) * 1990-04-06 1991-10-10 Degussa Verbindungen zur bekaempfung von pflanzenkrankheiten
EP0471236B1 (en) * 1990-07-30 1995-03-15 Takeda Chemical Industries, Ltd. Imidazopyridine derivatives and their use
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
US6090785A (en) * 1992-10-15 2000-07-18 Merck & Co., Inc. Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5455262A (en) * 1993-10-06 1995-10-03 Florida State University Mercaptosulfide metalloproteinase inhibitors
US5470834A (en) * 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
US6022898A (en) * 1994-06-22 2000-02-08 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
KR100429950B1 (ko) * 1995-07-31 2004-06-16 시오노기세이야쿠가부시키가이샤 포스포리파제에이2저해활성을갖는피롤리딘유도체
SI0874830T1 (en) * 1995-12-08 2003-08-31 Agouron Pharmaceuticals, Inc. A metalloproteinase inhibitor, a pharmaceutical composition containing it and the pharmaceutical use and method useful for the preparation thereof

Also Published As

Publication number Publication date
BR9712792A (pt) 1999-12-14
PL331803A1 (en) 1999-08-02
US6121272A (en) 2000-09-19
NO990896D0 (no) 1999-02-25
HUP0000616A2 (en) 2000-07-28
TR199900401T2 (xx) 1999-05-21
SK24899A3 (en) 2000-04-10
IL128665A0 (en) 2000-01-31
ZA977697B (en) 1998-02-23
WO1998008814A1 (en) 1998-03-05
CN1228767A (zh) 1999-09-15
KR20000035921A (ko) 2000-06-26
EP0923547A1 (en) 1999-06-23
PE109298A1 (es) 1999-01-31
CZ62499A3 (cs) 1999-07-14
CO5420196A1 (es) 2004-07-30
CA2263914A1 (en) 1998-03-05
JP2000516954A (ja) 2000-12-19
ID18417A (id) 1998-04-09
AU4074097A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
NO990896L (no) Bidentate metalloproteaseinhibitorer
PL331802A1 (en) Substituted cyclic amines as metaloprotease inhibitors
CA2264254A1 (en) Phosphinic acid amides as matrix metalloprotease inhibitors
NO20024521L (no) Heterocyklisk sidekjede-inneholdende metalloproteaseinhibitorer
NO990760L (no) 1,4-heterocykliske metallproteaseinhibitorer
WO1999006340A3 (en) Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
BR9909620A (pt) Inibidores de metaloproteases de hidroxamato de pirrolidina substituìdo
NO973035L (no) Hydroksaminsyre-holdige inhibitorer for matriks-metallproteaser
CA2367017A1 (en) Inhibitors of impdh enzyme
WO2003024448A3 (en) Inhibitors of histone deacetylase
FI942423A (fi) Sakkariinijohdannisia proteolyyttisen entsyymin inhibiittoreina
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
AU6894800A (en) Caspase inhibitors and uses thereof
WO2000051993A3 (en) Dihetero-substituted metalloprotease inhibitors
BR0008716A (pt) Inibidores de metaloprotease contendo alquenil ou alquinil
NO984740L (no) Isatinderivater som acetylcholinesteraseinhibitorer og analgetiske midler
BR0109328A (pt) Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
EA199900057A1 (ru) Ингибиторы матриксных металлопротеиназ
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
NO20014241L (no) C16-umettede FP-selektive prostaglandinanaloger
WO2001070720A3 (en) Carbocyclic side chain containing, n-substituted metalloprotease inhibitors
WO2001070693A3 (en) Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
BR0014759A (pt) Inibidores de metaloprotease beta dissubstituìdos
NO20011038L (no) Substituerte dihydrobenzopyraner nyttige som antiarytmiske midler
ATE271384T1 (de) Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application